Idiosyncratic drug-induced liver injury: an overview

Hussaini, S. H.; Farrington, Elizabeth

doi:10.1517/14740338.6.6.673

Cited by 170 publications

(109 citation statements)

References 102 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…Although the risk of liver damage related to NSAID use is thought to be rare, several reviews have identified NSAIDs as the most common drugs to cause liver injury. 32,[84][85][86][87][88][89][90] The estimated incidence of NSAID-associated hepatotoxicity is between 3 and 23 per 100,000 patientyears. 87 Risk factors for NSAID-induced hepatotoxicity include P = 0.025 for ibuprofen Table 2).…”

Section: 78mentioning

confidence: 99%

NSAIDs for Musculoskeletal Pain Management: Current Perspectives and Novel Strategies to Improve Safety

Atchison¹,

Herndon²,

Rusie³

2013

JMCP

View full text Add to dashboard Cite

and completed residency training in physical medicine and rehabilitation at The Ohio State University. Dr. Atchison has been in practice at academic medical centers for more than 20 years, serving on the faculty at the University of Kentucky and University of Florida before his appointment at Northwestern University. A recognized teacher and researcher in the field of pain management and rehabilitation, he has presented courses, lectures, and workshops nationally and internationally on pharmacological and nonpharmacological therapies, care of spinal injuries, and spinal manipulation. Dr. Atchison has led and participated in many research projects, including several funded by the National Institutes of Health. He has authored numerous research papers and book chapters, and he serves as a peer reviewer for the Archives of Physical Medicine and Rehabilitation. He has been a member of the editorial boards of the Supplement Policy Statement Standards for Supplements to the Journal of Managed Care PharmacySupplements to the Journal of Managed Care Pharmacy are intended to support medical education and research in areas of clinical practice, health care quality improvement, or efficient administration and delivery of health benefits. The following standards are applied to all JMCP supplements to ensure quality and assist readers in evaluating potential bias and determining alternate explanations for findings and results. 1. Disclose the principal sources of funding in a manner that permits easy recognition by the reader. 2. Disclose the existence of all potential conflicts of interest among supplement contributors, including financial or personal bias. 3. Describe all drugs by generic name unless the use of the brand name is necessary to reduce the opportunity for confusion among readers. 4. Identify any off-label (unapproved) use by drug name and specific off-label indication. 5. Strive to report subjects of current interest to managed care pharmacists and other managed care professionals. S14 Multitarget Drugs S15 Conclusions S15 References Target AudiencesThis CME/CE activity is designed to meet the educational needs of pharmacists, physicians, nurse practitioners, and nurses. Learning Objectives• Assess patient-specific risk factors in selecting NSAIDs for mild-to-moderate musculoskeletal pain • Incorporate risk/benefit analysis in decision making about NSAID use • Use evidence-based guidelines for selecting NSAID therapy and applying strategies to prevent complications • Evaluate the efficacy, safety, and pharmacological profile of new and emerging NSAID formulations Funding This supplement was funded by an independent educational grant to PRIME Education, Inc. (PRIME) from Iroko Pharmaceuticals, LLC. Accreditation StatementsIn support of improving patient care, PRIME Education, Inc. (PRIME) is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing educat...

show abstract

Section: 78mentioning

confidence: 99%

NSAIDs for Musculoskeletal Pain Management: Current Perspectives and Novel Strategies to Improve Safety

Atchison¹,

Herndon²,

Rusie³

2013

JMCP

View full text Add to dashboard Cite

show abstract

“…The mechanisms are explained in more detail below. The type of liver injury induced by a potential hepatotoxic agent can be classified clinically by the relative rise of alanine aminotransferase (ALT) and alkaline phosphatase (ALP) [Hussaini and Farrington, 2007]. The pathogenesis involves direct hepatotoxicity by the drug or a reactive metabolite, and adverse immune reactions, usually triggered by hepatic damage [Holt and Ju, 2006].…”

Section: Mechanisms Of Dilimentioning

confidence: 99%

Drug-induced liver injury in older adults

Mitchell

Hilmer

2010

Therapeutic Advances in Drug Safety

View full text Add to dashboard Cite

Drug-induced liver injury (DILI) is an important cause of hospitalisation and of medication deregistration. In old age, susceptibility to DILI is affected by changes in physiology and increased interindividual variability, compounded by an increased prevalence of disease and the frailty syndrome. While dose-related or predictable DILI reactions are often detected in preclinical trials, the occurrence of rare hypersensitivity or idiosyncratic reactions cannot be reliably predicted from preclinical studies or even by clinical trials. The limited participation of older adults in clinical trials means that the susceptibility of this population to DILI is largely unknown. Vigilance during clinical trials and postmarketing surveillance must be universally practised. A systematic approach should be taken to determine not only which medicines are hepatotoxic and should be removed from the market, but also the hepatotoxicity risks from marketed drugs to consumers with different characteristics, many of whom are older people.

show abstract

“…It is unpredictable, and usually occurs after a latent period [37]. It is a rare cause of severe liver disease.…”

Section: Dili Can Be Classified As Followsmentioning

confidence: 99%

Cellular and Molecular Aspects of Drug-Induced Liver Toxicity: Recent Prominent Mechanisms

Erkekoğlu¹

2015

MOJT

View full text Add to dashboard Cite

Despite recent advances in drug development technologies, some drugs continue to be withdrawn from the market because of their late hepatotoxic effects. Drugs can cause liver toxicity through several molecular mechanisms, most of which need to be clarified by further research. Newly found drug-induced liver injury (DILI)-mechanisms like endoplasmic reticulum stress should also be considered while evaluating drug toxicity. New drugs launched in the market should be tested particularly for hepatotoxicity by using hepatic cell cultures and animal models continuously. Future research should target patients in the post-marketing phase in order to provide more evidence grounds to the clinical safety of potential drugs of high propensity of DILI. This review aims to draw the attention to the issue of cellular and molecular aspects of liver toxicity induced by drugs and address DILI as a potential clinical problem that needs further investigation.

show abstract

Idiosyncratic drug-induced liver injury: an overview

Cited by 170 publications

References 102 publications

NSAIDs for Musculoskeletal Pain Management: Current Perspectives and Novel Strategies to Improve Safety

NSAIDs for Musculoskeletal Pain Management: Current Perspectives and Novel Strategies to Improve Safety

Drug-induced liver injury in older adults

Cellular and Molecular Aspects of Drug-Induced Liver Toxicity: Recent Prominent Mechanisms

Contact Info

Product

Resources

About